BRCA1 mRNA expression as a predictive and prognostic marker in advanced esophageal squamous cell carcinoma treated with cisplatin- or docetaxel-based chemotherapy/chemoradiotherapy.

Abstract

BACKGROUND:

The molecular backgrounds that determine therapeutic effectiveness in esophageal cancer remain largely unknown. Breast cancer susceptibility gene 1 (BRCA1) expression has been found to switch the response to cisplatin- or paclitaxel-based chemotherapy. It remains unclear how variations in BRCA1 expression influence clinical outcomes in esophageal cancer.

PATIENTS AND METHODS:

Quantitative real-time polymerase chain reaction (qPCR) was performed to examine BRCA1 mRNA expressions in paraffin-embedded specimens from 144 patients with advanced or metastatic esophageal squamous cell carcinoma who received cisplatin- or docetaxel-based first-line treatments.

RESULTS:

Low BRCA1 mRNA expression correlated with increased response rate (RR; P = 0.025 and 0.017, respectively) and median overall survival (mOS; P = 0.002 and P<0.001, respectively) in cisplatin-based chemotherapy or chemoradiotherapy group and also correlated with decreased RR (P = 0.017 and 0.024, respectively) and mOS (both P<0.001) in docetaxel-based chemotherapy or chemoradiotherapy group. Multivariate analysis revealed that low BRCA1 expression was an independent prognostic factor in cisplatin-based chemotherapy (HR 0.29; 95%CI 0.12-0.71; P = 0.007) or chemoradiotherapy (HR 0.12; 95%CI 0.04-0.37; P<0.001) group and higher risk for mortality in docetaxel-based chemotherapy (HR 5.02; 95%CI 2.05-12.28; P<0.001) or chemoradiotherapy (HR 7.02; 95%CI 2.37-27.77; P<0.001) group.

CONCLUSIONS:

BRCA1 mRNA expression could be used as a predictive and prognostic marker in esophageal cancer who underwent first-line cisplatin- or docetaxel-based treatments.

• Authors: Yong Gao, Jing Zhu, Xiaohui Zhang, Qingquan Wu, Shaoning Jiang, Yangqing Liu, Zhibin Hu, Baorui Liu, Xiaofei Chen
• Journal: PloS one (PLoS One) Vol. 8 Issue 1 Pg. e52589 ( 2013) ISSN: 1932-6203 [Electronic] United States
• PMID: 23326344 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• BRCA1 Protein
• Biomarkers, Tumor
• RNA, Messenger
• Taxoids
• Docetaxel
• Cisplatin

Topics

• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• BRCA1 Protein (genetics)
• Biomarkers, Tumor (genetics)
• Carcinoma, Squamous Cell (genetics, pathology, therapy)
• Chemoradiotherapy
• Cisplatin (administration & dosage)
• Docetaxel
• Esophageal Neoplasms (genetics, pathology, therapy)
• Female
• Gene Expression Regulation, Neoplastic
• Humans
• Kaplan-Meier Estimate
• Male
• Middle Aged
• Multivariate Analysis
• Outcome Assessment, Health Care (statistics & numerical data)
• Predictive Value of Tests
• Prognosis
• Proportional Hazards Models
• RNA, Messenger (genetics, metabolism)
• Reverse Transcriptase Polymerase Chain Reaction
• Taxoids (administration & dosage)